Business Context and Reporting Period
This Form 8-K Current Report, dated July 30, 2021, covers events occurring on August 2, 2021, for Keros Therapeutics, Inc., a biopharmaceutical company incorporated in Delaware. The filing primarily addresses executive leadership changes within the company's medical leadership team.
Key Financial Metrics
This filing does not contain comprehensive financial statements, revenue, profit, cash flow, or debt metrics. The only specific financial figures disclosed relate to executive compensation and severance arrangements:
- Dr. Simon Cooper (New CMO): Annual base salary of $450,000; target annual discretionary bonus of 40% of base salary ($180,000); stock option grant for up to 60,000 shares.
- Dr. Claudia Ordonez (Departing CMO): Cash severance equivalent to nine months of base salary; COBRA reimbursement for up to nine months; acceleration of vesting on 7,603 unvested stock options; consulting fee of $5,000; outplacement services reimbursement up to $6,000.
Material Changes
The primary material change reported is the transition of the Chief Medical Officer (CMO) role:
- Departure: Dr. Claudia Ordonez departed the CMO position effective July 30, 2021. She will provide consulting services until September 15, 2021.
- Appointment: Dr. Simon Cooper was appointed as the new Chief Medical Officer, effective August 2, 2021.
Outlook, Risks, and Management Commentary
Management Commentary: The company highlighted Dr. Cooper's extensive experience, including previous roles as CMO at Kadmon Holdings, Anokion SA, and leadership positions at AbbVie, Sanofi, and Novartis. The appointment is intended to strengthen the company's clinical development capabilities.
Compensation Structure and Risks: Dr. Cooper's employment is "at-will." The agreement includes specific severance protections: nine months of salary and COBRA for involuntary termination without cause; 12 months of salary, full equity acceleration, and a lump-sum bonus payment in the event of a change of control followed by termination without cause or resignation for good reason.
Contingencies: The filing notes that Dr. Ordonez's separation agreement includes confidentiality, non-competition, non-disparagement, and non-solicitation covenants. Dr. Cooper is subject to similar covenants for 12 months post-employment.
Key Facts for Investor Verification
- Verify the impact of the CMO transition on the company's ongoing clinical trial timelines and regulatory strategy.
- Review the full text of the Separation Agreement (Exhibit 10.1) and Employment Agreement (Exhibit 10.2) for detailed terms regarding equity vesting and change-of-control provisions.
- Monitor the company's cash burn rate relative to the new executive compensation commitments, as this filing does not provide current liquidity data.
- Confirm the status of Dr. Ordonez's consulting period and the handover of clinical responsibilities through September 15, 2021.